Cargando…

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives

SIMPLE SUMMARY: Urothelial bladder cancer (BC) is one of the most fatal cancers, with a dismal five-year survival rate of 5% in patients with metastatic disease. Clinically relevant benefits of immunotherapy in advanced or metastatic bladder cancer have led to Food and Drug Administration (FDA) appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roviello, Giandomenico, Catalano, Martina, Santi, Raffaella, Palmieri, Valeria Emma, Vannini, Gianmarco, Galli, Ilaria Camilla, Buttitta, Eleonora, Villari, Donata, Rossi, Virginia, Nesi, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431680/ https://www.ncbi.nlm.nih.gov/pubmed/34503220 http://dx.doi.org/10.3390/cancers13174411

Ejemplares similares

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity following Chemotherapy
por: Becattini, Lucrezia, et al.
Publicado: (2022)

Inflammation in Urological Malignancies: The Silent Killer
por: Catalano, Martina, et al.
Publicado: (2023)

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
por: Cosso, Federica, et al.
Publicado: (2023)

Immune combinations and complete response: a new hope for metastatic renal cell carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Angiosarcoma of the Urinary Bladder Following Radiotherapy: Report of a Case and Review of the Literature
por: Cito, Gianmartin, et al.
Publicado: (2021)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
por: Lavacchi, Daniele, et al.
Publicado: (2023)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Current Knowledge of the Potential Links between Inflammation and Prostate Cancer
por: Cai, Tommaso, et al.
Publicado: (2019)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Inverted urothelial papilloma of the upper urinary tract: description of two cases with systematic literature review
por: Santi, R., et al.
Publicado: (2020)

Second line of treatment for HER2-positive gastric cancer: an evolving issue
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Editorial: Microbiota and metabolites in cancer immunotherapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Prostate Cancer Characteristics in Renal Transplant Recipients: A 25-Year Experience From a Single Centre
por: Spatafora, Pietro, et al.
Publicado: (2021)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer
por: Basile, Debora, et al.
Publicado: (2021)

Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and −186 expression: Novel mechanism of VEGF modulation in prostate cancer
por: Terzuoli, Erika, et al.
Publicado: (2016)

Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art
por: Califano, Gianluigi, et al.
Publicado: (2022)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
por: Catalano, Martina, et al.
Publicado: (2020)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—what is currently known?
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas
por: Catalano, Martina, et al.
Publicado: (2021)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
por: Catalano, Martina, et al.
Publicado: (2022)

The distinctive nature of adenocarcinoma of the lung
por: Roviello, Giandomenico
Publicado: (2015)

Gastric and colonic metastasis from NSCLC: A very unusual case report
por: Catalano, Martina, et al.
Publicado: (2022)

mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity
por: Finetti, Federica, et al.
Publicado: (2015)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8ud7sv907vfueohnk1gbfjvafl